Rosalind Advisors, Inc. recently announced the acquisition of new stake in Galera Therapeutics Inc. (NASDAQ:GRTX). This fresh investment now brings its stake to 5.42% valued currently at $2.55 million. In addition, Geode Capital Management LLC raised its holdings by 86287.0 to 0.17 million shares. And Northern Trust Investments, Inc. has lifted its position by 61.02% or 11091.0 shares – to 29266.0 shares.
With over 0.71 million Galera Therapeutics Inc. (GRTX) shares trading Tuesday and a closing price of $1.90 on the day, the dollar volume was approximately $1.35 million. The shares have shown a positive half year performance of 47.29% and its price on 01/10/23 gained nearly 14.80%. Currently, there are 28.50M common shares owned by the public and among those 27.00M shares have been available to trade.
Top 5 Undervalued Stocks To Own In 2023
Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.
Click here to download your Free Research Report…
Sponsored
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 4 analysts who have offered their price forecasts for GRTX have a consensus price objective of $11.25. The analysts have set the share’s price value over the next 12 months at a high of $18.00 and a low of $2.00. The average price target is 81.0% above its recent price level and an upside to the estimated low will see the stock gain 5.0% over that period. But an upside of 89.44% will see the stock hit the forecast high price target while median target price for the stock is $12.50.
Insiders at the company have transacted a total of 3 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 2 of these insider trades were purchases, accounting for 20,000 shares. Insider sales of the common stock occurred on 1 occasions, with total insider shares sold totaling 4,000 shares.
The top 3 mutual fund holders in Galera Therapeutics Inc. are Vanguard Total Stock Market Index, Tekla Healthcare Opportunities Fu, and Tekla Healthcare Investors. Vanguard Total Stock Market Index owns 0.38 million shares of the company’s stock, all valued at over $0.63 million. The company bought an additional 84833.0 shares recently to bring their total holdings to about 1.34% of the shares outstanding. Tekla Healthcare Investors now owns shares totaling to 1.04% of the shares outstanding.
However, the script later moved the day high at 2.0000, up 14.80%. The company’s stock has a 5-day price change of 28.38% and 16.56% over the past three months. GRTX shares are trading 27.52% year to date (YTD), with the 12-month market performance down to -44.61% lower. It has a 12-month low price of $1.12 and touched a high of $3.83 over the same period. GRTX has an average intraday trading volume of 114.31K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 22.09%, 18.62%, and 18.12% respectively.
Institutional ownership of Galera Therapeutics Inc. (NASDAQ: GRTX) shares accounts for 40.10% of the company’s 28.50M shares outstanding. Mutual fund holders own 6.44%, while other institutional holders and individual stakeholders account for 7.98% and 20.64% respectively.
It has a market capitalization of $51.39M. The earnings-per-share (ttm) stands at -$2.35. Price movements for the stock have been influenced by the stock’s volatility, which stands at 9.46% over the week and 9.71% over the month.
Analysts forecast that Galera Therapeutics Inc. (GRTX) will achieve an EPS of -$0.5 for the current quarter, -$0.41 for the next quarter and -$1.15 for 2023. The lowest estimate earnings-per-share for the quarter is -$0.56 while analysts give the company a high EPS estimate of -$0.45. Comparatively, EPS for the current quarter was -$0.86 a year ago. Earnings per share for the fiscal year are expected to decrease by -4.60%, and 41.60% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 4 brokerage firm advisors rate Galera Therapeutics Inc. (GRTX) as a “Moderate Buy” at a consensus score of 2.00. Specifically, 3 Wall Street analysts polled rate the stock as a buy, while 0 of the 4 advise that investors “hold,” and 0 rated it as a “Sell.”
BofA Securities coverage for the Galera Therapeutics Inc. (GRTX) stock in a research note released on October 19, 2021 offered a Underperform rating with a price target of $2. Credit Suisse was of a view on April 26, 2021 that the stock is Outperform, while Credit Suisse gave the stock Outperform rating on December 16, 2020, issuing a price target of $9- $15. H.C. Wainwright on their part issued Buy rating on December 07, 2020.
